# The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

> **NCT06058585** · PHASE3 · RECRUITING · sponsor: **The George Institute** · enrollment: 1000 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Finerenone
- **DRUG:** Placebo Finerenone

## Key facts

- **NCT ID:** NCT06058585
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2028-08-30
- **Final completion:** 2029-03-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058585, "The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06058585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*